According to the latest report by IMARC Group, titled “Onychomycosis Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” The global onychomycosis treatment market reached a value of US$ 2.94 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 4.12 Billion by 2027, exhibiting at a CAGR of 5.50% during 2022-2027.
Onychomycosis refers to a fungal infection that causes discoloration, thickening, and separation of the nails. It can be treated through medications, laser therapy, and photodynamic therapies. Its treatment is usually given based on the type of fungus causing infection, the number of affected nails, and the severity of nail involvement.
Onychomycosis is a common nail disorder among senior citizens and athletes caused by organisms, such as dermatophytes, non-dermatophyte molds, and yeasts. This, in confluence with the rising geriatric population, which is highly prone to circulatory disorders and weakened immune system, is strengthening the market growth. Besides this, the increasing number of individuals who use occlusive footwear, shared bathing facilities, and public swimming pools is augmenting the risk of developing onychomycosis and catalyzing the demand for enhanced onychomycosis treatment. In addition to this, the development of water-soluble anti-fungal treatment solutions that can be administered orally is propelling the market growth.
Request for a free sample copy of this report: https://www.imarcgroup.com/onychomycosis-treatment-market/requestsample
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Competitive Landscape with Key Player:
- Bausch Health Companies Inc.
- Cipla Limited
- Dr. Reddy’s Laboratories
- Galderma SA
- GlaxoSmithKline PLC
- Kaken Pharmaceutical Co. Ltd
- Lumenis Ltd
- Moberg Pharma AB
- Novartis AG
- Pfizer Inc
- The OTC Lab B.V.
Breakup by Disease Type:
- Distal Subungual Onychomycosis
- Proximal Subungual Onychomycosis
- White Superficial Onychomycosis
- Candidal Onychomycosis
Breakup by Treatment Type:
- Laser Therapy
- Photodynamic Therapy
- Drug Treatment
Breakup by Drug Class:
Breakup by Distribution Channel:
- Hospitals and Clinics
- Online Stores
- Retail Pharmacies
Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/onychomycosis-treatment-market
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800